Treatment with icatibant in the management of drug induced angioedema.

Abstract

Acute, drug-induced angioedema may not respond to standard therapies, because the pathogenetic mechanism that induces the pathology is not always mediated by histamine but, in certain instances, by bradykinin. A case of angioedema is reported here, in which allergic etiology was excluded by the non-response to antihistamines. Considering the clinical history (repeated use of drugs) and the ineffectiveness of standard therapy, it was decided to administer a beta2 receptor antagonist, icatibant. After 20 minutes, the patient reported a subjective improvement. The only form of angioedema for which this type of medication is licensed is the hereditary deficiency of C1 inhibitor. The use of icatibant for the treatment of other types of angioedema (which can also be life-saving if the airway is involved) is off label. The off-label use of a drug is allowed in the absence of a viable alternative therapy, if there is scientific evidence in the literature and if the prescriber takes responsibility. The case here reported draws attention to this therapeutic problem and underlines the fact that a life-threatening emergency can justify the use of icatibant.

• Authors: G Bertazzoni, E Bresciani, L Cipollone, E Fante, R Galandrini
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 19 Issue 1 Pg. 149-53 (Jan 2015) ISSN: 2284-0729 [Electronic] Italy
• PMID: 25635988 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Allergic Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Bradykinin B2 Receptor Antagonists
• icatibant
• Bradykinin

Topics

• Aged
• Angioedema (chemically induced, drug therapy)
• Anti-Allergic Agents (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Bradykinin (analogs & derivatives, therapeutic use)
• Bradykinin B2 Receptor Antagonists (therapeutic use)
• Female
• Humans
• Off-Label Use